Stelara: Royalty Headwinds and Contractual Guardrails
Stelara (ustekinumab), with its $17 billion in global sales, is preparing for US biosimilar competition in 2025. But J&J’s approach in structuring market entry is unusual. Behind closed doors, settlements are setting the pace, Amgen’s ABP 654 and Samsung Bioepis’s SB17 won’t launch until late 2025 at the earliest. Even though biosimilars have secured global approvals and launches are underway in Europe this year, US entry is being staggered by design. So, the kind of swift price collapse seen with Humira just isn’t on the immediate horizon.
When biosimilars do enter, the shakeup looks subdued. J&J’s fortress of patents and tightly drawn contracts shield Stelara from the worst of price wars, at least for now. Consensus from most sell-side models puts first-year US net price erosion around 30-40%, a far cry from the 85% net collapse Humira weathered. Pharmacy benefit managers (PBMs) have signaled they’ll leverage new entrants against each other, but they’re not going to pull the rug on pricing, particularly in immunology where switching remains a hassle and there are so few initial challengers.
Royalty-bearing deals add another layer of complexity. Alvotech, Celltrion, and others are all cutting royalty checks to J&J, which means biosimilar savings are spread thinner. Hospital systems expecting another Humira-like windfall will need to recalibrate. Stelara’s revenue drop to an estimated $10-12 billion by 2027 looks less like a cliff and more like a managed descent. Still big money, just not the old days. New biosimilar launches and pricing details are best tracked at RxInfo.ai, which keeps up as numbers shift.
What Happens When Keytruda’s Moat Is Tested?
Keytruda (pembrolizumab) stands apart from yesterday’s blockbuster biologics. With $24 billion in annual oncology sales, it’s shielded by a web of clinical indications, intricate infusion logistics, and a physician community steeped in the originator. The first US biosimilar exclusivity drops as soon as 2028, but the real drama could begin in 2026 or 2027 as early FDA filings start to pile up. Fresenius Kabi, Sandoz, and Amgen are all chasing pembrolizumab biosimilars, each advancing candidates through the pipeline.
Still, Keytruda’s economics defy simple analogies. Hospitals and clinics are paid based on ASP plus 6%, so net biosimilar price erosion tracks slowly with shifting Medicare benchmarks. If biosimilars nab 20% share in year one with prices 35% lower, the fiscal impact across payers will be fragmented, and in some markets, practically invisible. Nobody’s kidding themselves: this won’t be a Humira rerun.
The manufacturing hurdles are more acute here than in any other biosimilar wave. Keytruda biosimilars cost a small fortune, $150-250 million each to develop, more than double the price of, say, a TNF-inhibitor copy. Only a handful of late-stage programs are moving forward, including Fresenius’ MSB11456 and Sandoz’s SP-07. Merck’s stranglehold on supply doesn’t make it any easier. PBMs know what’s coming, and they’re already preparing for a slow ramp, as tracked by PBM economic impacts here.
So oncology biosimilars, especially in first-line settings, are poised to rewrite the typical script. Sure, list prices will drop, but the true costs, after rebates, copay cards, and buy-and-bill incentives, remain opaque. Hard to measure savings, easy to argue over them.
Eylea: A Case Study in Pricing Chess
Regeneron’s Eylea (aflibercept) is a $9 billion-a-year juggernaut in ophthalmology, and the biosimilar and generic arms race is heating up. The regulatory paths look straightforward, but the reality is a maze. Amgen and Samsung Bioepis landed FDA approvals for aflibercept biosimilars last year; US market entry is locked down until 2026 by patent settlements. Meanwhile, Regeneron isn’t sitting still. They’ve launched Eylea HD, a high-dose version straight out of the small-molecule lifecycle playbook, complicating switching strategies for both payers and doctors.
Price competition is inevitable, but the trajectory is anything but clean. The list price of standard Eylea hovers around $1,850 per dose in the US, but heavy discounts, now 25-30% off, are already in play as retina clinics negotiate tough terms. By 2026, expect biosimilar aflibercept to undercut the originator by 35-45%. Uptake, though, depends on much more than price. Payer step-edits, buy-and-bill incentives, and whether Regeneron can pivot volume to Eylea HD all play a role. Uptake could stall if new SKUs stick.
For retina specialists, it’s all about the margins. Biosimilar adoption will be sluggish unless clinics see clear economic upside. Push payers too hard and clinics can dig in their heels, citing nuanced patient needs. And really, who can blame them? Pricing, rebates, and discount trends are all live on RxInfo.ai. Expect those numbers to keep moving as dealmaking heats up and rebate schemes get more complicated.
Pipeline and Deal Strategies: Stand-Offs and Dropouts
Biosimilar pipelines are buzzing, but with risk at every turn. Probably six or more ustekinumab biosimilars will have the FDA’s green light by 2025, yet thanks to layered settlements, just a couple will actually launch on day one. Keytruda has five legitimate late-stage contenders, but frankly, with development costs climbing and regulatory risks looming, it wouldn’t surprise anyone to see one or more shift strategies or bow out entirely.
Attrition comes down to cost, timing, and plain old bad luck. Oncology biosimilar programs burn through capital, and the clinical bar rises each year. Immunogenicity setbacks or failed endpoints quickly add millions to the tab. With aflibercept, the science is less daunting now, but commercial success depends on brokering trust with retina clinics, not just low prices. In these markets, relationships outmaneuver discounts.
Deal-making is morphing fast. Confidential settlements are now the default; few manufacturers have the appetite for drawn-out legal battles after watching the Humira saga. So the critical details, timelines, royalty rates, which biosimilar is “authorized”, are hammered out behind the scenes, often before the FDA even weighs in. It makes for a landscape where the news headlines can lag the actual reality. For ongoing deal news, RxNews.ai keeps the running tally.
Stelara, Keytruda, and Eylea are the test cases for how US payers, providers, and manufacturers handle biosimilar disruption this time around. The savings are coming. Just not as fast, or in the way, anyone got last decade. And if you’re looking for a clean ending, there just isn’t one. Deals, numbers, and competitive quirks are changing faster than the ink dries on analysis.
